NCT00549692View on ClinicalTrials.gov

Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy

PHASE3CompletedINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

August 31, 2012

Study Completion Date

September 30, 2012

Conditions
IgA Nephropathy
Interventions
DRUG

Omega-3 fatty acid ethylester90

Dosage form :1g soft capsule Dosage : two capsules, twice a day.

Trial Locations (5)

463-707

Seoul National University Bundang Hospital, Seongnam

110-740

Seoul National University Hospital, Seoul

130-702

Kyhung Hee University medical center, Seoul

135-710

Samsumg Medical Center, Seoul

137-701

Kangnam St. May's Hospital, Seoul

Sponsors
All Listed Sponsors
collaborator

Pronova BioPharma ASA

INDUSTRY

lead

Kuhnil Pharmaceutical Co., Ltd.

INDUSTRY

NCT00549692 - Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy | Biotech Hunter | Biotech Hunter